Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Find insight on the outlook for deals in the banking sector, risks for Canada’s large banks and more in the latest Market Talks covering Financial Services.

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...